Source: Eur Respir J 2016; 47: 588-596
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Solomon Joshua J., Chung Jonathan H., Cosgrove Gregory P., Demoruelle M. Kristen, Fernandez-Perez Evans R., Fischer Aryeh, Frankel Stephen K., Hobbs Stephen B., Huie Tristan J., Ketzer Jill, Mannina Amar, Olson Amy L., Russell Gloria, Tsuchiya Yutaka, Yunt Zulma X., Zelarney Pearlanne T., Brown Kevin K., Swigris Jeffrey J.. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47: 588-596

Member's Comments

No comment yet.

Related content which might interest you: Predicting outcomes in rheumatoid arthritis related interstitial lung disease Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018 Year: 2019 Duration of rheumatoid arthritis and the risk of developing interstitial lung disease Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020 Year: 2021 Mortality and clinical features in rheumatoid arthritis and interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Interstitial lung disease in patients with rheumatoid arthritis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Methotrexate and rheumatoid arthritis associated interstitial lung disease Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020 Year: 2021 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease Source: International Congress 2015 – Connective tissue disorders Year: 2015 Characteristics and predictors of outcome in rheumatoid arthritis related ILD Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Rheumatoid arthritis-associated interstitial lung disease: time trends Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Incidence, prevalence and mortality of rheumatoid arthritis-associated interstitial lung disease : a retrospective study Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2010; 35: 1322-1328 Year: 2010 Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2010; 35: 1206-1208 Year: 2010 Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new Source: Breathe, 16 (4) 200223; 10.1183/20734735.0223-2020 Year: 2020 Rheumatoid arthritis-associated lung disease Source: Eur Respir Rev 2015; 24: 1-16 Year: 2015 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 A prognostic staging system for rheumatoid arthritis-associated interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018